^
Association details:
| Biomarker: | ADRB2 overexpression |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
170P - ß2-adrenergic receptor gene expression as a prognostic and predictive biomarker in HER2-positive early-stage breast cancer patients enrolled on the NCCTG-N9831 (Alliance) trial
Published date:
09/14/2020
Excerpt:
ADRB2-high was associated with a longer DFS in patients from arms B&C (p<0.01), but not in those from arm A (p=0.63).
Trial ID:
